Alexion Challenges Federal Authority to Regulate Drug Prices

Overview

Food and Drug Law
Food and Drug Regulatory Law
On September 11, U.S.-based Alexion Pharmaceuticals Inc. filed a Notice of Application against the Canadian Patented Medicine Prices Review Board (the PMPRB). Alexion Pharmaceuticals is requesting a declaration that the price regulation regime under the Canadian Patent Act exceeds the powers granted to Parliament under the Constitution Act and improperly extends into the provincial jurisdiction over property and civil rights. 

The PMPRB is seeking to determine whether the price for Alexion Pharmaceuticals’ drug product Soliris (a drug that treats two types of rare blood disorders) is “excessive.” Hearings into Soliris’ pricing were launched in June, to which Alexion Pharmaceuticals responded by submitting the above-mentioned Federal Court motion. The Federal Court proceedings are currently underway.

For more information on the dispute, click here.

Follow our FDL updates us on Twitter: @TorysFDL
MailClick here to subscribe to Torys' insights and updates

Lawyers